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Chronic Granulomatous
Disease, Catalase,
and Actinomyces
To the Editor—We read with interest
the article “Actinomyces in Chronic Gran-
ulomatous Disease: An Emerging and Un-
anticipated Pathogen” by Reichenbach et
al [1]. However, we do not believe this
series of patients with chronic granulo-
matous disease (CGD) and Actinomyces
infection demonstrates compelling evi-
dence to dismiss the traditionally recog-
nized risk factor of microbial catalase as
the most important virulence factor in pa-
tients with CGD unless phenotypic-neg-
ative catalase results from the species iso-
lated in this series are made available.
Actinomyces infection in patients with
CGD should not necessarily be consid-
ered as supporting evidence for a differ-
ent mechanism of virulence, because Ac-
tinomyces species are not universally cat-
alase negative, as was suggested in the ar-
ticle [1]. It is notable that, of the 8
Actinomyces isolates identified to the spe-
cies level, 7 were identified as Actinomyces
naeslundii (6 specimens had positive cul-
ture results, and 1 specimen had positive
serological test results). The genospecies
type 2 of A. naeslundii is catalase-positive
in ∼55% of isolates, and 30% of all geno-
species isolates of A. naeslundii were cat-
alase positive in one dental study [2]. Oc-
casionally, other Actinomyces species can
be catalase positive, as well [3]. In a recent
review of 92 clinically significant strains of
Actinomyces species identified by 16S ri-
bosomal DNA analysis, no isolates were
identified as A. naeslundii, which high-
lighted the infrequency of this organism
as a cause of clinically significant disease
in patients without CGD [4].
Without this essential biochemical data,
the conclusion that the “susceptibility of
patients with CGD to infection with cat-
alase-negative Actinomyces species con-
firms that catalase production is neither
necessary nor sufficient for microbial vir-
ulence in CGD” is not supported by this
article [1, pp 1708–1709]. Rather, catalase
positivity, which is frequently found in A.
naeslundii, may still explain most of these
infections. In conclusion, this series may
not significantly depart from the tradi-
tional association of catalase-positive mi-
crobial infections and CGD. Although cat-
alase-negative infections in patients with
CGD have been described, the frequency
of such infections, compared with those
due to catalase-producing organisms, and
the importance of alternative mechanisms
require further investigation.
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Reply to Agger and Kowalski
To the Editor—We appreciate the com-
ments of Drs Agger and Kowalski, which
echo the traditional assumption that mi-
crobial catalase production is the “most
important virulence factor in patients with
chronic granulomatous disease [CGD]”
[1, p. 1325]. They rightly point out that
Actinomyces can be variable in terms of
catalase production, and although the ma-
jority of strains are catalase negative, a sig-
nificant number may be catalase inter-
mediate or even catalase positive. How-
ever, because Actinomyces are generally
considered to be catalase negative, and be-
cause most are, we thought it important
to point out that they do, in fact, cause
significant morbidity in CGD. Although it
is true that most pathogens associated with
CGD are catalase positive, that is a general
truism applicable to all pathogens that af-
fect humans: most pathogens are catalase
producing, with the broad exception of the
streptococci. We cited several strong lines
of clinical and basic evidence that support
our assertion that catalase is not per se a
necessary virulence factor in CGD infec-
tions. First, deletion of catalase from
Staphylococcus aureus did not change its
virulence in a mouse model of CGD [2].
Second, deletion of catalase from Asper-
gillus nidulans did not change its viru-
lence in a mouse model of CGD [3].
Third, numerous case reports and cases
from our current series are clearly caused
by catalase negative organisms, negating
catalase as a necessary virulence factor in
CGD [4]. Drs Agger and Kowalski are
correct that we did not study every strain
of Actinomyces for catalase production,
and there are indeed catalase-positive
strains of Actinomyces naeslundii. We did
study the National Institutes of Health–
isolated strains for catalase production
with use of standard techniques and
found them (from patients 3, 4, 5, and
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8 [5]) to be catalase negative. There-
fore—although the allure of the catalase
hypothesis is strong, its directness of ex-
planation is soothing, and it has long-
standing prominence in the field—the
clinical and laboratory evidence over-
whelmingly indicates that catalase is nei-
ther necessary nor sufficient for virulence
in CGD.
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Staphylococcal Toxic Shock
Syndrome, Superantigenicity,
and Hypersensitivity
To the Editor—With great interest, we
read the article by Chandy et al [1] con-
cerning staphylococcal toxic shock syn-
drome (TSS) and its association with su-
perantigenicity and hypersensitivity. The
authors describe a 16-year-old girl who
presented with severely acidotic hyper-
glycemia and concomitant Staphylococcus
bacteremia, with accompanying TSS with-
out rash or desquamation. Blood and
urine cultures revealed methicillin-sus-
ceptible Staphylococcus aureus. The pa-
tient was treated with clindamycin for 5
days, cefazolin for 14 days, and immu-
noglobulin (1 mg/kg).
The authors state that 10% of S. aureus
strains produce enterotoxin, but the prev-
alence of TSS is much lower than 10%.
Another explanation for this clinical pic-
ture is septic shock associated with com-
munity-acquired S. aureus bloodstream
infection. Furthermore, the enterotoxin
production could be an innocent by-
stander. Also, the patient did not meet
the criteria for TSS because there was no
rash or desquamation, but she did meet
the criteria for community-acquired S.
aureus bloodstream infection [2]. Giv-
en the limited clinical evidence for effi-
cacy of immunoglobulin and clindamy-
cin for the treatment of staphylococcal
TSS, it seems unlikely that there was a
causal relationship between the adminis-
tration of clindamycin and immunoglob-
ulin and the hemodynamic improvement
after administration.
Therefore, we concluded that this pa-
tient had a complicated S. aureus blood-
stream infection that was acquired in the
community [2, 3]. This infection has a
high risk of hematogenous complications,
and although there was no accompany-
ing endocarditis, a recent review in this
journal recommended at least 4 weeks
of high-dose anti-staphylococcal peni-
cillin for community-acquired S. aureus
bloodstream infection [2, 3]. The asso-
ciated urine culture also grew S. aureus,
and the patient had type 1 diabetes. Both
factors are also associated with hematog-
enous complications and, possibly, pro-
vide an extra argument in favor of at least
4 weeks of high-dose therapy [4, 5].
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Reply to Landman
and Groeneveld
To the Editors—We appreciate the in-
terest of Landman and Groeneveld [1] in
our study. They note that the child de-
scribed in our article may have had septic
shock due to community-associated
Staphylococcus aureus infection rather than
staphylococcal toxic shock syndrome
(TSS). We cannot state definitively that the
child had staphylococcal TSS, because all
of the diagnostic criteria for staphylococ-
cal TSS other than erythroderma and de-
squamation—the 2 criteria that the pa-
tient lacked—are common to both TSS
and septic shock. It is also noteworthy that
the presence of septic shock does not pre-
clude the patient from having TSS. Al-
though the majority of patients with
staphylococcal TSS do not have blood cul-
tures positive for S. aureus, a significant
